Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
Sunstone Medical Research, LLC
mi
from
Medford, OR
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
Urologic Consultants of Southeast Pennsylvania
mi
from
Bala-Cynwyd, PA
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
Urologic Consultants of Southeast Pennsylvania
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
Research Across America
mi
from
Carrollton, TX
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
Research Across America
mi
from
Carrollton, TX
Click here to add this to my saved trials
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
Research Across America
mi
from
Dallas, TX
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
Research Across America
mi
from
Dallas, TX
Click here to add this to my saved trials
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated:  12/31/1969
University of Bonn, Clinic for Dermatology and Allergy
mi
from
Bonn,
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men
Status: Enrolling
Updated: 12/31/1969
University of Bonn, Clinic for Dermatology and Allergy
mi
from
Bonn,
Click here to add this to my saved trials
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated:  12/31/1969
ProSciento, Inc.
mi
from
Chula Vista, CA
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated: 12/31/1969
ProSciento, Inc.
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated:  12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated: 12/31/1969
AMCR Institute, Inc
mi
from
Escondido, CA
Click here to add this to my saved trials
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated:  12/31/1969
Rainier Clinical Research
mi
from
Renton, WA
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A Randomized, Double-blind, Parallel-group Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus (T1DM) Compared to Placebo
Status: Enrolling
Updated: 12/31/1969
Rainier Clinical Research
mi
from
Renton, WA
Click here to add this to my saved trials
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
UF Health Children's Hospital
mi
from
Gainesville, FL
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
UF Health Children's Hospital
mi
from
Gainesville, FL
Click here to add this to my saved trials
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
mi
from
Gainesville, FL
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
UF Health Pediatrics - Gerold L. Schiebler CMS Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated:  12/31/1969
Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building
mi
from
Gainesville, FL
Introducing CGM at Type 1 Diabetes Diagnosis
Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study
Status: Enrolling
Updated: 12/31/1969
Pediatrics Endocrinology/Diabetes at UF Health Medical Plaza and Children's Medical Services Building
mi
from
Gainesville, FL
Click here to add this to my saved trials
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Phase II Study of Decitabine in Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Radioiodine
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)
Status: Enrolling
Updated:  12/31/1969
HeartDrug Research, LLC
mi
from
Towson, MD
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)
Status: Enrolling
Updated: 12/31/1969
HeartDrug Research, LLC
mi
from
Towson, MD
Click here to add this to my saved trials
Bisphenol A and Muscle Insulin Sensitivity
Randomized Trial Examining Oral Consumption of Bisphenol A on Type 2 Diabetes Risk Markers
Status: Enrolling
Updated:  12/31/1969
California Polytechnic State University
mi
from
San Luis Obispo, CA
Bisphenol A and Muscle Insulin Sensitivity
Randomized Trial Examining Oral Consumption of Bisphenol A on Type 2 Diabetes Risk Markers
Status: Enrolling
Updated: 12/31/1969
California Polytechnic State University
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Washington University: Siteman Cancer Center
mi
from
Saint Louis, MO
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Washington University: Siteman Cancer Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania Maloney Hospital
mi
from
Philadelphia, PA
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania Maloney Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Eastern Virginia Medical School
mi
from
Norfolk, VA
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy
A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy Administered Every Three Weeks by Venous Infusion by Patients With Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
University of Alabama
mi
from
Birmingham, AL
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
University of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Neufeld Medical Group
mi
from
Los Angeles, CA
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Neufeld Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Center of Excellence in Diabetes & Endocrinology
mi
from
Sacramento, CA
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Center of Excellence in Diabetes & Endocrinology
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
The Rocky Mountain Pediatric Endocrinology
mi
from
Centennial, CO
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
The Rocky Mountain Pediatric Endocrinology
mi
from
Centennial, CO
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Health System
mi
from
Jacksonville, FL
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Health System
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Orlando Health
mi
from
Orlando, FL
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Tallahassee Memorial Hospital
mi
from
Tallahassee, FL
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Tallahassee Memorial Hospital
mi
from
Tallahassee, FL
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Children's Minnesota
mi
from
Saint Paul, MN
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Children's Minnesota
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
NYU Winthrop Hospital
mi
from
Mineola, NY
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
NYU Winthrop Hospital
mi
from
Mineola, NY
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Children's Diabetes and Endocrine Center
mi
from
Portland, OR
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Children's Diabetes and Endocrine Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Children's Medical Center
mi
from
Dallas, TX
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Children's Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
University of Virginia Children's Hospital
mi
from
Charlottesville, VA
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
University of Virginia Children's Hospital
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated:  12/31/1969
Monash Children's Hospital
mi
from
Clayton,
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
Status: Enrolling
Updated: 12/31/1969
Monash Children's Hospital
mi
from
Clayton,
Click here to add this to my saved trials